New oral anticoagulants in primary care: The general practitioner's point of view

被引：0
作者：
Frappe, Paul [1 ,2 ,3 ]
Liebart, Sandra [1 ,2 ]
机构：
[1] Univ St Etienne, Dept Med Gen, F-42023 St Etienne, France
[2] Univ St Etienne, Grp Rech Thrombose, EA3065, F-42023 St Etienne, France
[3] Inserm DGOS, CIE3, F-42055 St Etienne, France
来源：
PRESSE MEDICALE | 2013年 / 42卷 / 09期
关键词：
ATRIAL-FIBRILLATION; DECISION-MAKING; RISK; DABIGATRAN; MANAGEMENT; PHYSICIANS; COMMUNITY; WARFARIN; PATIENT; DRUGS;
D O I：
10.1016/j.lpm.2013.06.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The assessment of new anticoagulants benefits is based on the assessment of thromboembolism and bleeding risks, referring when possible to CHA(2)DS(2)-VASc and HAS-BLED scores. The management of patients treated with new anticoagulants includes a clinical assessment and the annual measure of the creatinine clearance (three times per year in some particular cases). New anticoagulants make hemostasis tests not reliable. The general practitioner has a role in preventing interactions and reporting potential adverse drug reactions. The context of uncertainty about the risk/benefit ratio of new anticoagulants emphasizes the need to integrate the values of the patient in treatment decisions.
引用
收藏
页码：1267 / 1273
页数：7
相关论文
共 50 条
  • [21] Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants
    Ebner, Matthias
    Peter, Andreas
    Spencer, Charlotte
    Haertig, Florian
    Birschmann, Ingvild
    Kuhn, Joachim
    Wolf, Martin
    Winter, Natalie
    Russo, Francesca
    Zuern, Christine S.
    Blumenstock, Gunnar
    Ziemann, Ulf
    Poli, Sven
    STROKE, 2015, 46 (10) : 2741 - 2747
  • [22] Adoption of new medicines in primary care: A comparison between the uptake of new oral anticoagulants and diabetes medicines
    Dankers, Marloes
    Hek, Karin
    Mantel-Teeuwisse, Aukje K.
    van Dijk, Liset
    Nelissen-Vrancken, Marjorie H. J. M. G.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (03) : 819 - 827
  • [23] Use of Direct Oral Anticoagulants in Canadian Primary Care Practice 2010-2015: A Cohort Study From the Canadian Primary Care Sentinel Surveillance Network
    McAlister, Finlay A.
    Garrison, Scott
    Kosowan, Leanne
    Ezekowitz, Justin A.
    Singer, Alexander
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (03):
  • [24] Einsatz der Neuen oralen Antikoagulanzien in HausarztpraxenUse of New Oral Anticoagulants in Primary Care Practices
    Markus Bleckwenn
    Karoline Dinkel
    Klaus Weckbecker
    Martin Mücke
    Zeitschrift für Allgemeinmedizin, 2016, 92 (1): : 28 - 32
  • [25] Monitoring the efficiency of reversal on anti-Xa direct oral anticoagulants using point-of-care viscoelastic testing
    Heubner, Lars
    Grottke, Oliver
    Vicent, Oliver
    Spieth, Peter Markus
    Beyer-Westendorf, Jan
    THROMBOSIS JOURNAL, 2024, 22 (01):
  • [26] Expert Opinion on the Use of Novel Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation for the Primary Care Setting in India: A Literature Review
    Dalal, Jamshed
    Poncha, Fali
    Bansal, Sandeep
    Das, Arvind
    Gupta, Praveen
    Ghosh, Debasis
    Rohatgi, Anshu
    Hiremath, Murugesh S.
    Bhargava, Kartikeya
    Gopi, Arun
    Mali, Mithun
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (05)
  • [27] Adolescent behavioural risk screening in primary care: physician's point of view
    Eisner-Fellay, Taslina
    Suris, Joan-Carles
    Barrense-Dias, Yara
    FAMILY PRACTICE, 2024, 41 (02) : 123 - 130
  • [28] Blood pressure levels and risk of haemorrhagic stroke in patients with atrial fibrillation and oral anticoagulants: results from The Swedish Primary Care Cardiovascular Database of Skaraborg
    Bager, Johan-Emil
    Hjerpe, Per
    Schioler, Linus
    Bengtsson Bostrom, Kristina
    Kahan, Thomas
    Odesjo, Helena
    Jood, Katarina
    Hasselstrom, Jan
    Ljungman, Charlotta
    Manhem, Karin
    Mourtzinis, Georgios
    JOURNAL OF HYPERTENSION, 2021, 39 (08) : 1670 - 1677
  • [29] Current situation of direct oral anticoagulants in primary care in Spain: Positioning of SEMERGEN in 2023
    Polo-Garcia, J.
    Pallares-Carratala, V.
    Turegano-Yedro, M.
    Romero-Vigara, J. C.
    Prieto-Diaz, M. A.
    Cinza-Sanjurjo, S.
    MEDICINA DE FAMILIA-SEMERGEN, 2024, 50 (03):
  • [30] Laboratory Monitoring: A Turning Point in the Use of New Oral Anticoagulants
    Scridon, Alina
    Serban, Razvan C.
    THERAPEUTIC DRUG MONITORING, 2016, 38 (01) : 12 - 21
12345